SRR5903558
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.540
- G2M_CHECKPOINT+0.460
- ALLOGRAFT_REJECTION+0.450
- INTERFERON_GAMMA_RESPONSE+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.340
- INTERFERON_ALPHA_RESPONSE+0.340
- MYC_TARGETS_V1+0.300
- PANCREAS_BETA_CELLS+0.300
- TNFA_SIGNALING_VIA_NFKB+0.300
- SPERMATOGENESIS+0.280
Top 10 suppressed
- PROTEIN_SECRETION-0.490
- TGF_BETA_SIGNALING-0.340
- HEME_METABOLISM-0.310
- NOTCH_SIGNALING-0.280
- ADIPOGENESIS-0.260
- CHOLESTEROL_HOMEOSTASIS-0.260
- PEROXISOME-0.260
- BILE_ACID_METABOLISM-0.180
- OXIDATIVE_PHOSPHORYLATION-0.180
- ESTROGEN_RESPONSE_EARLY-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_4989_T2_RNA | — | C | 0.803 |
| 2 | SRR8518367 | — | D | 0.802 |
| 3 | MDT-AP-0732 | Med | Medulloblastoma | 0.802 |
| 4 | MNG1120 | — | — | 0.801 |
| 5 | F5EB77B4-61AD-40EC-B5B0-44D2D5AD66D7 | — | — | 0.796 |
| 6 | BS_J1AB8PMA | medulloblastoma | — | 0.795 |
| 7 | TCGA-OL-A66I-01A-21R-A29R-07 | — | D | 0.794 |
| 8 | SRR29022833 | — | D | 0.783 |
| 9 | C3L-02954 | — | cohortA1 | 0.783 |
| 10 | MNG1010 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.540 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.340 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |
| COMPLEMENT | 0.240 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| HYPOXIA | 0.170 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |